Showing 6611-6620 of 8649 results for "".
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Researchers Identify Genes and Cell Types That May Have Causal Role in POAG Formationhttps://modernod.com/news/researchers-identify-genes-and-cell-types-that-may-have-causal-role-in-poag-formation/2482119/In a new study published in Nature Communications, researchers from Mass Eye and Ear conducted a comprehensive study that combined genetic discoveries from a large cross-ancestry genome-wide association study meta-analysis of primary open-angle glaucoma (POAG), and a large
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- FDA Gives Green Light to Okyo Pharma for Clinical Trial Design for OK-101 in Neuropathic Corneal Painhttps://modernod.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/Okyo Pharma announced that the FDA has cleared OK-101 as its first investigational new drug (IND) application for the treatment of Neuropathic Corneal Pain (NCP). The initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positiv
- Iridex Receives European Patent on MicroPulse Technologyhttps://modernod.com/news/iridex-receives-european-patent-on-micropulse-technology/2482102/Iridex announced the grant of the European Patent 'EP 3009093,' titled "Laser System with Short Pulse Characteristics and its Methods of Use.” This patent protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields for '
- Iridex Enrolls First Patient in MicroPulse TLT Study in Collaboration with Imperial College Healthcare NHS Trusthttps://modernod.com/news/iridex-enrolls-first-patient-in-micropulse-tlt-study-in-collaboration-with-imperial-college-healthcare-nhs-trust/2482081/Iridex and Imperial College Healthcare NHS Trust in London announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse Transscleral Laser Therapy (TLT) using the Iridex Cyclo G6 Laser and th
- KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implantshttps://modernod.com/news/keralink-international-provides-25-million-in-seed-funding-to-enable-development-of-bioengineered-corneal-implants/2481970/KeraLink International (KLI) announced $2.5 million in seed funding in Pantheon Vision (PV) to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs). Pantheon Vision, an early-stage ophthalmic med
- OIG Publishes General Compliance Program Guidance for the Health Care Industryhttps://modernod.com/news/oig-publishes-general-compliance-program-guidance-for-the-health-care-industry/2481964/According to an advisory from law firm Arnold & Porter, on November 6, the Department of Health and Human Services Office of Inspector General (OIG) released a
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- CooperVision to Present New Scientific Findings on Presbyopia Correction and Myopia Management at Academy ‘23https://modernod.com/news/coopervision-to-present-new-scientific-findings-on-presbyopia-correction-and-myopia-management-at-academy-23/2481873/CooperVision’s researchers and partners are scheduled to present multiple scientific posters at the